Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dyne Therapeutics, Inc. (Nasdaq: DYN) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Dyne is a clinical-stage biopharmaceutical company focused on genetically driven neuromuscular diseases, and its filings offer detailed insight into its programs, financing activities and risk disclosures.
Investors can review current reports on Form 8-K, where Dyne reports material events such as quarterly financial results, public offerings of common stock, loan and security agreements, regulatory designations for its product candidates and changes to its board of directors. For example, recent 8-K filings describe underwritten public offerings of DYN common stock, a term loan facility with Hercules Capital, Inc., Breakthrough Therapy Designation for DYNE-251, and director appointments.
Through Dyne’s registration statements and prospectus supplements referenced in its filings, users can track details of equity offerings made under its shelf registration on Form S-3. Filings also identify that DYN common stock is registered under Section 12(b) of the Exchange Act and listed on the Nasdaq Global Select Market.
On Stock Titan, these documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as financing terms, cash runway statements, clinical and regulatory milestones referenced in disclosure, and covenant structures in loan agreements. Users can follow new 8-Ks and other submissions as they are made available through EDGAR, and use the summarized content to orient themselves before consulting the full text of each filing.
Dyne Therapeutics director-affiliated funds reported open-market sales of 384,549 shares of common stock at prices generally around $18–$19 per share. The trades on April 23–27 were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026.
The shares were sold by Atlas Venture funds and related partnerships, including Atlas Venture Opportunity Fund II, Atlas Venture Fund XI, AVA XI LP, and Atlas Venture Opportunity Fund I. Jason P. Rhodes is a member of the relevant general partner entities and disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.